Latest Revenue Guidance News

Atturra Limited confirms its FY26 revenue and EBITDA guidance, acknowledging a contract termination impact in H1 but optimistic about a stronger second half.

Acrow Limited reaffirms its first half FY26 revenue guidance with a 22% increase year-on-year, driven by robust demand in key Australian regions and strategic capital investments.

PEXA Group has announced its strategic exit from majority-owned Digital Solutions businesses, triggering a $26 million impairment and a restatement of its FY26 financial guidance. The move signals a sharper focus on core operations amid restructuring costs.

AVITA Medical closed 2025 with steady revenue growth and over 80% gross margin, setting the stage for a confident revenue forecast of up to US$85 million in 2026. The company also secured a new debt facility with improved terms, underpinning its growth ambitions.

AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.

Amaero Ltd reported a remarkable 367% revenue increase to A$7.76 million for H1 FY2026, supported by a $50 million capital raise and exclusive supply agreements with industry leaders. Despite widening losses, the company is accelerating capacity expansion and securing key partnerships in aerospace and defence.

Bravura Solutions has raised its FY26 revenue and cash EBITDA guidance, reflecting robust project engagement and disciplined cost management. The company also plans increased investment in internal technology.

SKS Technologies Group has upgraded its FY26 earnings forecast following $60 million in new contract awards, including major projects for NEXTDC and Ernst & Young. The company anticipates stronger revenue and profit margins driven by robust demand in data centre infrastructure.

Jcurve Solutions has reported a robust Q2FY26 with a significant profit turnaround and a confident revenue outlook for FY26, driven by strong sales and recurring revenue growth.

Jcurve Solutions has reported a robust first half of FY26, posting a 32% increase in revenue and a remarkable 478% jump in EBITDA, while upgrading its full-year revenue guidance amid ongoing customer churn challenges.

Aroa Biosurgery’s latest business update reveals promising clinical outcomes from its Myriad trauma study and evolving reimbursement policies that could reshape its market position. The company also projects solid revenue growth for FY26, supported by strategic commercial initiatives.

Aroa Biosurgery reaffirms strong FY26 guidance, buoyed by favourable US Medicare reimbursement for Symphony and promising trauma study results for Myriad.